Gatekeeping astrocyte identity

Related Articles:

• ELOVL me tender October 20, 2021 # # # # Astrocytes are a non-neuronal cell type in the brain that play an important supportive role – nurturing neurons and helping to maintain homeostasis in the central nervous system. When neurons get damaged or stressed, however, astrocytes can do a Jekyll & Hyde-like transformation and start releasing a toxic substance that helps to kill neurons. This nasty…
• Gatekeeping astrocyte identity June 20, 2022 Elife. 2022 Jun 20;11:e80232. doi: 10.7554/eLife.80232.ABSTRACTNew findings cast doubt on whether suppressing the RNA-binding protein PTBP1 can force astrocytes to become dopaminergic neurons.PMID:35723428 | DOI:10.7554/eLife.80232
• Gatekeeping astrocyte identity June 20, 2022 Elife. 2022 Jun 20;11:e80232. doi: 10.7554/eLife.80232.ABSTRACTNew findings cast doubt on whether suppressing the RNA-binding protein PTBP1 can force astrocytes to become dopaminergic neurons.PMID:35723428 | DOI:10.7554/eLife.80232
• Gatekeeping astrocyte identity June 20, 2022 Elife. 2022 Jun 20;11:e80232. doi: 10.7554/eLife.80232.ABSTRACTNew findings cast doubt on whether suppressing the RNA-binding protein PTBP1 can force astrocytes to become dopaminergic neurons.PMID:35723428 | DOI:10.7554/eLife.80232
• Gatekeeping astrocyte identity June 20, 2022 Elife. 2022 Jun 20;11:e80232. doi: 10.7554/eLife.80232.ABSTRACTNew findings cast doubt on whether suppressing the RNA-binding protein PTBP1 can force astrocytes to become dopaminergic neurons.PMID:35723428 | DOI:10.7554/eLife.80232
• Gatekeeping astrocyte identity June 20, 2022 Elife. 2022 Jun 20;11:e80232. doi: 10.7554/eLife.80232.ABSTRACTNew findings cast doubt on whether suppressing the RNA-binding protein PTBP1 can force astrocytes to become dopaminergic neurons.PMID:35723428 | DOI:10.7554/eLife.80232
• Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson's disease May 10, 2022 Elife. 2022 May 10;11:e75636. doi: 10.7554/eLife.75636. Online ahead of print.ABSTRACTLineage reprograming of resident glial cells to dopaminergic neurons (DAns) is an attractive prospect of the cell-replacement therapy for Parkinson's disease (PD). However, it is unclear whether repressing polypyrimidine tract binding protein 1 (PTBP1) could efficiently convert astrocyte to DAns in the substantia nigra and striatum. Although reporter-positive DAns were observed…
• Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson's disease May 10, 2022 Elife. 2022 May 10;11:e75636. doi: 10.7554/eLife.75636. Online ahead of print.ABSTRACTLineage reprograming of resident glial cells to dopaminergic neurons (DAns) is an attractive prospect of the cell-replacement therapy for Parkinson's disease (PD). However, it is unclear whether repressing polypyrimidine tract binding protein 1 (PTBP1) could efficiently convert astrocyte to DAns in the substantia nigra and striatum. Although reporter-positive DAns were observed…
• Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson's disease May 10, 2022 Elife. 2022 May 10;11:e75636. doi: 10.7554/eLife.75636. Online ahead of print.ABSTRACTLineage reprograming of resident glial cells to dopaminergic neurons (DAns) is an attractive prospect of the cell-replacement therapy for Parkinson's disease (PD). However, it is unclear whether repressing polypyrimidine tract binding protein 1 (PTBP1) could efficiently convert astrocyte to DAns in the substantia nigra and striatum. Although reporter-positive DAns were observed…
• Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson's disease May 10, 2022 Elife. 2022 May 10;11:e75636. doi: 10.7554/eLife.75636. Online ahead of print.ABSTRACTLineage reprograming of resident glial cells to dopaminergic neurons (DAns) is an attractive prospect of the cell-replacement therapy for Parkinson's disease (PD). However, it is unclear whether repressing polypyrimidine tract binding protein 1 (PTBP1) could efficiently convert astrocyte to DAns in the substantia nigra and striatum. Although reporter-positive DAns were observed…
• Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson's disease May 10, 2022 Elife. 2022 May 10;11:e75636. doi: 10.7554/eLife.75636. Online ahead of print.ABSTRACTLineage reprograming of resident glial cells to dopaminergic neurons (DAns) is an attractive prospect of the cell-replacement therapy for Parkinson's disease (PD). However, it is unclear whether repressing polypyrimidine tract binding protein 1 (PTBP1) could efficiently convert astrocyte to DAns in the substantia nigra and striatum. Although reporter-positive DAns were observed…
• Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson's disease May 10, 2022 Elife. 2022 May 10;11:e75636. doi: 10.7554/eLife.75636. Online ahead of print.ABSTRACTLineage reprograming of resident glial cells to dopaminergic neurons (DAns) is an attractive prospect of the cell-replacement therapy for Parkinson's disease (PD). However, it is unclear whether repressing polypyrimidine tract binding protein 1 (PTBP1) could efficiently convert astrocyte to DAns in the substantia nigra and striatum. Although reporter-positive DAns were observed…
• Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson's disease May 10, 2022 Elife. 2022 May 10;11:e75636. doi: 10.7554/eLife.75636. Online ahead of print.ABSTRACTLineage reprograming of resident glial cells to dopaminergic neurons (DAns) is an attractive prospect of the cell-replacement therapy for Parkinson's disease (PD). However, it is unclear whether repressing polypyrimidine tract binding protein 1 (PTBP1) could efficiently convert astrocyte to DAns in the substantia nigra and striatum. Although reporter-positive DAns were observed…
• A Healthy New Identity Helps When Battling a Chronic Disease March 29, 2019 Identity, the “I” in CHRONDI Creed, refers to the process of finding a health-fostering identity in the face of a chronic disease that has stolen things we loved to do and caused the death of self. When everything I loved to do was taken from me, all that was left was the time and energy I was putting into managing the…
• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• Not dead, dormant dopamine neurons?!? January 18, 2020   Every textbook written about the condition will tell you that the classical pathological characteristic of Parkinson’s is the loss of dopamine neurons in the midbrain region of the brain. It is the distinguishing feature that pathologists look for in order to provide a postmortem diagnosis of the condition. But what is meant by the words ‘loss of dopamine neurons’?…
• Yo DJ, stop mis-splicing November 16, 2020 # # # # RNA – the usable copy of a section of DNA – has regions called introns that need to be removed before the RNA can be used for the production of protein. The process of removing introns is called splicing. Recently researchers have noticed that a genetic mutation in a Parkinson’s-associated gene – called DJ-1 – affects…
• A.S.A.P September 26, 2019       Yesterday the Aligning Science Across Parkinson’s (ASAP) initiative published a point of view in the scientific journal eLife. It laid out the objectives, themes and philosophy of an enormous new scientific effort to better understand Parkinson’s. The overall project is being led by a Nobel prize winner scientist and employing the considerable resources of a very wealthy…
• Monthly Research Review – October 2021 October 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during October 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• A New Year’s Resolution: Quiet the Old Tapes January 4, 2019 In my column about time management, I mentioned a nagging inner voice saying, “You did not get enough done today.” That phrase ties to an old “tape,” inner dialogue left by the voices of parents and childhood teachers that says, “You are never going to amount to anything. You are a bad person.” The inner drive to continually produce is an…
• The Neuraly trial November 5, 2019       This week a new clinical trial was registered which caught our attention here at the SoPD HQ. It is being sponsored by a small biotech called Neuraly and involves a drug called NLY01. NLY01 is a GLP-1R agonist – that is a molecule that binds to the Glucagon-like peptide-1 receptor and activates it. Other GLP-1R agonists include…
• Abnormal Brain Cell Type Leads to Parkinson’s-Related Neurodegeneration, Study Contends January 11, 2019 Scientists have found that an abnormal version of brain cells called astrocytes contribute to the accumulation of alpha-synuclein protein, the main component of Parkinson’s disease hallmark Lewy bodies. Their study, “Patient-specific iPSC-derived astrocytes contribute to non-cell autonomous neurodegeneration in Parkinson’s disease,” was published in Stem Cell Reports. Parkinson’s disease is linked to degeneration of the ventral midbrain (relating to the…